Intra-Cellular Therapies Overview
Intra-Cellular Therapies (ITCI) has a P/E ratio of -183.15, below the Healthcare sector average of 27.42.
Get informed when a big investor buys or sells
+ Follow-183.15
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, ITCI shows a P/E ratio of -183.15. That is below the Healthcare sector average of 27.42. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 27.42. Intra-Cellular Therapies is at -183.15, which is lower that average. That is roughly 767.8% below the sector mean. Use the comparison chart on this page to see how ITCI stacks up against individual peers as well.
Investors watch ITCI's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Intra-Cellular Therapies's latest reading is -183.15. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Intra-Cellular Therapies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -183.15) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 27.42, while ITCI is at -183.15. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
